Mount Sinai Logo

M. Margaret Kemeny

  • PROFESSOR Surgery
Print ProfilePrint Profile

Education

  • B.S., Harvard College

  • M.D., Columbia University, College of Physicians and Surgeons

  • Memorial Sloan-Kettering Cancer Center
    Tumor Oncology

  • Memorial Sloan-Kettering Cancer Center
    Thoracic Surgery

  • Downstate Medical Center
    Surgery

Awards

  • 2000 -
    Surgeon of the Year Award
    Surgical Residents, SUNY Stony Brook

  • 1998 -
    Teacher of the Year Award
    Surgical Residents, North Shore University Hospital

  • 1972 -
    Award for Scholastic Achievement
    American Medical Women's Association, Inc.

Research

Schering-Plough Research Institute, Gene Therapy of Primary and Metastatic Malignant\r\nTumors of the Liver Using SCH 58500 (rAd/p53) Via Hepatic Artery Infusion: A\r\nPhase I Study

\r\n

A Two-Stage Phase II Safety and Efficacy\r\n Study of Intradose (Cisplatin/Epinephrine) Injectable Gel Administered to Patients\r\n with Unresectable Intrahepatic Colorectal Metastases

\r\n

A Two-Stage Phase II Safety and Efficacy\r\n Study of IntraDose (Displatin/Epinephrine) Injectable Gel Administered to Patients\r\n with Unresectable Primary Hepatocellular Carcinoma

\r\n

The Long Island Breast Cancer Study Project

\r\n

CALGB protocol 9481: Phase III Study of Hepatic Artery FUDR, Leucovorin (LV)\r\n and Dexamethasone versus systemic 5-Fu and LV as treatment for hepatic metastases\r\n from colorectal cancer

\r\n

ECOG Protocol 3292: Biologic correlates to response and survival in colon\r\n cancer

\r\n

NIH study: Genetics of Breast Cancer Among Women of Jewish Ancestry

\r\n

CALGB protocol 9670: Barriers to Participation of Older Women with Breast\r\n Cancer in Clinical Trials: A Pilot Study

\r\n

Intergroup protocol 9288, SWOG 8990: Combined modality treatment of hepatic\r\n metastases from colorectal cancer

\r\n

Intergroup protocol ECOG 1292, SWOG 9250, CALGB 9395: Phase III Intergroup\r\n prospectively randomiized trial of perioperative 5FU after curative resection\r\n followed by 5 FU/levamisole for patients with colon cancer

\r\n

Publications

Kemeny M. Chemotherapy after hepatic resection of colorectal metastases. Cancer Treatment Research 1994; 69: 121-128.

Busch E, Kemeny MM. Colorectal Cancer: Hepatic directed therapy-the role of surgery, regional chemotherapy, novel modalities. Sem Onc 1995 Oct; 22(5): 488-493.

Piedbois P, Buyse M, Kemeny N, Rougier P, Carlson R, Allen-Mersh T, O'Connell M, Chang A, Sondak V, Kemeny M, Levy E. Reappraisal of hepatic arterial Infusion in the Treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Nat Ca Inst 1996; 88(5): 252-257.

Busch E, Kemeny MM, Fremgen A, Osteen R, Winchester DP, Clive R. Patterns of Breast Cancer Care in the Elderly. Cancer 1996; 78: 101-111.

Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell MJ, Rougier P, Chang AE, Sondak VK, Kemeny MM, Allen-Mersh TG, Fagniez PL, LeBourgeois JP, Piedbois P. Economic Implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. Journal of the National Cancer Institute 1997; 89(11): 790-795.

Kemeny MM. Change in the use of breast-conserving surgery in Western Washington after the 1990 NIH consensus development conference. Archives Surgery 1997; 132: 423-424.

Kemeny MM. Is There a Role for Radical Surgery in Advanced Gallbladder Carcinoma. HPB Surgery 1997; 10(5): 335-338.

Kemeny MM. Hepatic Metastases from Colorectal Cancer. Tumori 1997 Jan-Feb; 83(1 Suppl): S26-S27.

Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg 1998; 175: 437-445.

Stellman SD, Djordjevic MV, Muscat JE, Gong L, Bernstein D, Citron ML, White A, Kemeny M, Busch E, Nafziger AN. Relative abundance of organochlorine pesticides and . Cancer Epidemiology, Biomarkers & Prevention 1998; 7(6): 489-496.

Ricci JL, Busch E, Kemeny MM. Advanced colorectal cancer: Hepatic metastasis - Surgery, Regional chemotherapy and Evolving Modalities. Advances in Onc 1998; 14(1): 17-24.

Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of Interleukin-2 without diminshing anti-tumor efficacy. Proc Nat Acad Sci 1998; 95: 4561-4566.

Stellman SD, Djordjevic M, Britton JA, Muscat JE, Citron ML, Kemeny M, Busch E, Gong L. Breast Cancer Risk in Relation to Adipose Concentrations of Organochlorine Pesticides and Polychlorinated Biphenyls in Long Island, New York. Cancer Epidemiology, Biomarkers & Prevention 2000; 9: 1241-1249.

Kemeny M. Adjuvant Therapy for Breast Cancer. NIH Concensus Statement 2000 November 1-3; 17(4): 1-35.

Kemeny MM, Busch-Devereaux E, Merriam LT, O'Hea BJ. Cancer Surgery in the Elderly. Hematology/Oncology Clinics of North America 2000; 14(1): 169-192.

Kemeny MM. The Surgical Aspects of the Totally Implantable Hepatic Artery Infusion Pump. Archives of Surgery 2001; 136: 348-352.

Kemeny MM. Hepatic artery infusion of chemotherapy after liver resection. Seminars in Colon & Rectal Surgery 2002 December; 13(4): 305-311.

Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O'Dwyer PJ, Benson 3rd AB. Combined Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination with Continuous Infusion of Chemotherapy: An Intergroup Study. J of Clin Onc 2002 March; 20(6): 1499-1505.

Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ, Cancer and Leukemia Group B . Survery of Oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinicical trials. Cancer 2002; 95: 989-996.

Kemeny MM, Peterson AB, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ. Barriers to clinical trial participation by older women with breast cancer. J Clin Onc 2003 June 15; 21: 2268-2275.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Kemeny did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Queens Hospital Room A-531
82-68 164th Street
Jamaica, NY 11432

Tel: 718-883-4031
Fax: 718-883-6295

Address

Mount Sinai Hospital of Queens
25-10 30th Ave
Long Island City, NY 11102